← boardnext 2026-12-31
TARS
Tarsus Pharmaceuticals, Inc.distress 1/10 · well-funded / low risk$56.54-2%today-31% from 52w high
Lead: Lyme Disease
Revenue
$162M
Liquidity
$393M
Runway
23.9 yrs
Shares 1y
+2%
Price & events
-20.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
-2.0%
1W
-14.6%
1M
-7.3%
3M
-17.3%
6M
+33.9%
1Y
+103.2%
2Y
+118.2%
5Y
+35.2%
All
Overview
- Market Cap
- $2.43B
- Enterprise Value
- $2.40B
- Volume
- 24.26K
- 52 Week Range
- $38.82 – $82.51
- Total Shares
- 43.02M
- Float Shares
- 32.11M
- Short %
- 14.15%
- % Held by Insiders
- 3.06%
- % Held by Institutions
- 109.98%
- RVOL
- 0.02x
- Beta
- 0.50
Pipeline stages · 1 programs
TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 2 | lotilaner | Ocular Rosacea | — | enrolling by invitation |
| 2027-10 Estimated 50% readout ~2027-11-15 | Phase 2 | TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose | Lyme Disease | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (1)
- XDEMVYLOTILANER2023 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $95 (+67% upside) · 9 analysts
- 2026-07-21GuggenheimBuy
- 2026-07-09HC Wainwright & Co.Buy
- 2026-05-04HC Wainwright & Co.Buy
- 2026-02-25OppenheimerOutperform
- 2026-02-25GuggenheimBuy
- 2025-12-09BarclaysOverweight
Competitors — Lyme Disease
Recent news
- 2026-07-21TARS Maintained by Guggenheim -- Price Target Lowered to $89.00 - GuruFocus
- 2026-07-21How Tarsus Pharmaceuticals Inc. (TARS) Affects Rotational Strategy Timing - Stock Traders Daily
- 2026-07-21TARS Maintained by Guggenheim -- Price Target Lowered to $89.00 - GuruFocus
- 2026-07-15Tarsus Pharmaceuticals Announces Executive Leadership Transition - VisionMonday.com
- 2026-07-14Tarsus Chief Commercial Officer Departs - Orange County Business Journal
- 2026-07-14Tarsus Pharmaceuticals commercial chief leaves company - MSN
- 2026-07-13Tarsus Pharmaceuticals (TARS) Announces Departure of Chief Comme - GuruFocus
- 2026-07-13[8-K] Tarsus Pharmaceuticals, Inc. Reports Material Event - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.